Altratech Ltd
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Diagnostics and Personalized Medicine
Altratech’s multidisciplinary team has developed a novel multimodal platform for the detection and quantification of infectious viruses, DNA, RNA, antibodies, and antigens. Incorporating PNA probes (co-developed with the NIH) and a proprietary CMOS semiconductor detection chip, the platform is the first to enable concurrent serology and nucleic acid detection within a single system.
Applications include accelerated drug discovery through protein and DNA/RNA biomarker monitoring, remote and home-based clinical trials, companion diagnostics, and portable point-of-care viral testing with PCR-level analytical sensitivity.
Altratech is led by an experienced serial-entrepreneur management team:
• CEO Dr. Tara Dalton – PCR genotyping microfluidics platform (acquired by Life Technologies Inc.)
• COO Dr. David McGuire – DNA sequencing library-prep microfluidics technology (acquired by BD Inc.)
• CTO Tim Cummins – low-cost CMOS semiconductor sensor technologies (acquired by Silicon Labs Inc.)
Company HQ City:
Cork
Company HQ State:
Cork
Company HQ Country:
Ireland
Year Founded:
2013
Lead Product in Development:
PNA-BeadCAP DNA/RNA/Antibody/Antigen platform for biomarker detection
CEO
Dr Tara Dalton CEO
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
One
When you expect your next catalyst update?
2H-2027
What is your next catalyst (value inflection) update?
Clinical Trials and market launch 2H-2027
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}